In Brief: EP MedSystems
This article was originally published in The Gray Sheet
Executive Summary
EP MedSystems: Clinical trials for the firm's Alert catheter system for internal cardioversion of atrial fibrillation began the week of Dec. 8 at Duke University Medical Center, the company says. The Alert catheter delivers low energy electrical impulses to the interior of the heart in order to convert AF to a normal heart rhythm. Two additional centers, the Medical Center of the University of Alabama Birmingham and Allegheny University of the Health Sciences, will soon be added to the study...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.